Cargando…
Emerging role of tumor cell plasticity in modifying therapeutic response
Resistance to cancer therapy is a major barrier to cancer management. Conventional views have proposed that acquisition of resistance may result from genetic mutations. However, accumulating evidence implicates a key role of non-mutational resistance mechanisms underlying drug tolerance, the latter...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541492/ https://www.ncbi.nlm.nih.gov/pubmed/33028808 http://dx.doi.org/10.1038/s41392-020-00313-5 |
_version_ | 1783591405381222400 |
---|---|
author | Qin, Siyuan Jiang, Jingwen Lu, Yi Nice, Edouard C. Huang, Canhua Zhang, Jian He, Weifeng |
author_facet | Qin, Siyuan Jiang, Jingwen Lu, Yi Nice, Edouard C. Huang, Canhua Zhang, Jian He, Weifeng |
author_sort | Qin, Siyuan |
collection | PubMed |
description | Resistance to cancer therapy is a major barrier to cancer management. Conventional views have proposed that acquisition of resistance may result from genetic mutations. However, accumulating evidence implicates a key role of non-mutational resistance mechanisms underlying drug tolerance, the latter of which is the focus that will be discussed here. Such non-mutational processes are largely driven by tumor cell plasticity, which renders tumor cells insusceptible to the drug-targeted pathway, thereby facilitating the tumor cell survival and growth. The concept of tumor cell plasticity highlights the significance of re-activation of developmental programs that are closely correlated with epithelial–mesenchymal transition, acquisition properties of cancer stem cells, and trans-differentiation potential during drug exposure. From observations in various cancers, this concept provides an opportunity for investigating the nature of anticancer drug resistance. Over the years, our understanding of the emerging role of phenotype switching in modifying therapeutic response has considerably increased. This expanded knowledge of tumor cell plasticity contributes to developing novel therapeutic strategies or combination therapy regimens using available anticancer drugs, which are likely to improve patient outcomes in clinical practice. |
format | Online Article Text |
id | pubmed-7541492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-75414922020-10-19 Emerging role of tumor cell plasticity in modifying therapeutic response Qin, Siyuan Jiang, Jingwen Lu, Yi Nice, Edouard C. Huang, Canhua Zhang, Jian He, Weifeng Signal Transduct Target Ther Review Article Resistance to cancer therapy is a major barrier to cancer management. Conventional views have proposed that acquisition of resistance may result from genetic mutations. However, accumulating evidence implicates a key role of non-mutational resistance mechanisms underlying drug tolerance, the latter of which is the focus that will be discussed here. Such non-mutational processes are largely driven by tumor cell plasticity, which renders tumor cells insusceptible to the drug-targeted pathway, thereby facilitating the tumor cell survival and growth. The concept of tumor cell plasticity highlights the significance of re-activation of developmental programs that are closely correlated with epithelial–mesenchymal transition, acquisition properties of cancer stem cells, and trans-differentiation potential during drug exposure. From observations in various cancers, this concept provides an opportunity for investigating the nature of anticancer drug resistance. Over the years, our understanding of the emerging role of phenotype switching in modifying therapeutic response has considerably increased. This expanded knowledge of tumor cell plasticity contributes to developing novel therapeutic strategies or combination therapy regimens using available anticancer drugs, which are likely to improve patient outcomes in clinical practice. Nature Publishing Group UK 2020-10-07 /pmc/articles/PMC7541492/ /pubmed/33028808 http://dx.doi.org/10.1038/s41392-020-00313-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Qin, Siyuan Jiang, Jingwen Lu, Yi Nice, Edouard C. Huang, Canhua Zhang, Jian He, Weifeng Emerging role of tumor cell plasticity in modifying therapeutic response |
title | Emerging role of tumor cell plasticity in modifying therapeutic response |
title_full | Emerging role of tumor cell plasticity in modifying therapeutic response |
title_fullStr | Emerging role of tumor cell plasticity in modifying therapeutic response |
title_full_unstemmed | Emerging role of tumor cell plasticity in modifying therapeutic response |
title_short | Emerging role of tumor cell plasticity in modifying therapeutic response |
title_sort | emerging role of tumor cell plasticity in modifying therapeutic response |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541492/ https://www.ncbi.nlm.nih.gov/pubmed/33028808 http://dx.doi.org/10.1038/s41392-020-00313-5 |
work_keys_str_mv | AT qinsiyuan emergingroleoftumorcellplasticityinmodifyingtherapeuticresponse AT jiangjingwen emergingroleoftumorcellplasticityinmodifyingtherapeuticresponse AT luyi emergingroleoftumorcellplasticityinmodifyingtherapeuticresponse AT niceedouardc emergingroleoftumorcellplasticityinmodifyingtherapeuticresponse AT huangcanhua emergingroleoftumorcellplasticityinmodifyingtherapeuticresponse AT zhangjian emergingroleoftumorcellplasticityinmodifyingtherapeuticresponse AT heweifeng emergingroleoftumorcellplasticityinmodifyingtherapeuticresponse |